Category Press Releases

Agenus’ BOTBAL Shows 42% 2-Year Survival

Agenus’ BOT/BAL Shows 42% 2-Year Survival in MSS CRC, Moves Toward FDA Registration

Agenus’ BOT/BAL Combo Delivers 42% Two-Year Survival in MSS Colorectal Cancer: Phase 3 Trial Aligned with FDA Agenus Inc., a pioneer in immuno-oncology, announced compelling new clinical results and regulatory progress for its combination therapy of botensilimab and balstilimab (BOT/BAL).…

Read MoreAgenus’ BOT/BAL Shows 42% 2-Year Survival in MSS CRC, Moves Toward FDA Registration
CorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment

CorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment

FDA Approves CorFlow’s MOCA-II IDE Pivotal Trial to Advance Breakthrough Heart Attack Technology CorFlow Therapeutics AG, a Swiss-based medtech innovator specializing in cardiovascular care and microvascular disease, has reached a major milestone in the development of its cutting-edge heart attack…

Read MoreCorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment
Life-Sciences-Firms-Embrace-AI-and-Partnerships-to-Drive-Change_

Life Sciences Firms Embrace AI and Partnerships to Drive Change

Life Sciences Firms Turn to AI and Strategic Partnerships to Accelerate Digital Transformation Life sciences companies are embracing artificial intelligence (AI), automation, and strategic collaborations to drive agility, innovation, and patient-centricity, according to the latest research report by Information Services…

Read MoreLife Sciences Firms Embrace AI and Partnerships to Drive Change
Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Alpha Cognition Reports Promising Preclinical Results for ALPHA-1062 in Military-Related Mild TBI Model Alpha Cognition Inc., a biopharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, has announced encouraging preclinical data supporting the continued development of ALPHA-1062 for the…

Read MoreAlpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in Mild TBI Model

Merck Names Neoclease as Recipient of 2025 North American Advance Biotech Grant

Neoclease Awarded Merck’s 2025 North American Advance Biotech Grant for Pioneering Gene-Editing Therapies Targeting Parkinson’s Disease Merck, a globally recognized leader in science and technology, has officially announced that Neoclease, an emerging biotech startup based in Boston, has been selected…

Read MoreMerck Names Neoclease as Recipient of 2025 North American Advance Biotech Grant

Volt Lithium to Launch Mobile Direct Lithium Extraction Unit in North Dakota’s Bakken Basin

Volt Lithium to Launch Mobile Direct Lithium Extraction Unit in North Dakota’s Bakken Basin Volt Lithium Corp. ansition to LibertyStream Infrastructure Partners has announced the final assembly and imminent deployment of its proprietary mobile Direct Lithium Extraction (DLE) unit in…

Read MoreVolt Lithium to Launch Mobile Direct Lithium Extraction Unit in North Dakota’s Bakken Basin